Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals) - Global Forecasts to 2026
The global pharmaceutical drug delivery market in terms of revenue was estimated to be worth $1,656.9 billion in 2021 and is poised to reach $2,206.5 billion by 2026, growing at a CAGR of 5.9% from 2021 to 2026.
Growth in the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, the growing biologics market, increasing R&D investments, technological advancements, and new product launches. Moreover, pharmaceutical and biopharmaceutical companies are focusing on R&D to develop new molecules for various therapeutic applications and drug delivery platforms. The companies invest heavily in R&D with the aim of delivering high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years. On the other hand, the risk of needlestick injuries and the increased pricing pressure are expected to limit the market's growth to some extent in the coming years.
To know about the assumptions considered for the study, Request for Free Sample Report
Pharmaceutical Drug Delivery Market Dynamics
Drivers: Growth in biologics market
Recognizing the potential for biologics manufacturing, companies, such as Evonik (Germany), have made several strategic developments. For instance, the company increased its production capacity by acquiring SurModics in 2021, which focuses on controlled-release parenteral applications. In addition, Evonik acquired complementary technologies, such as Boehringer Ingelheim’s RESOMER platform, to improve its capability in this market. Similarly, in 2019, WuXi Biologics announced the launch of WuXi Vaccines, a joint venture with Shanghai Hile Bio-Technology Co., Ltd. The companies entered into a strategic partnership under which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. The biopharmaceutical industry has witnessed the emergence of a new class of therapeutics, showing significant potential for new treatments in oncology, diabetes, and other disease areas.
Restraints: Risk of needlestick injuries
Needlestick injuries are one of the most serious health and safety threats:
- According to PharmaJet, in the US, around 600,000 to 800,000 needlestick injuries are reported every year.
- The Occupational Safety and Health Administration (OSHA) estimates that around 5.6 million workers in the US are at the risk of exposure to blood-borne pathogens due to needlestick injuries.
- Furthermore, the CDC estimates that an average of 385,000 needlestick injuries occur annually in US hospital settings.
- Similarly, in Europe, more than 1 million needlestick injuries are reported each year (Source: Becton, Dickinson and Company).
Opportunities: Self-administration and home care
Self-administration and home care are expected to provide significant growth opportunities for players operating in the pharmaceutical drug delivery market. This is mainly due to the rising geriatric population, as elderly individuals form a large consumer base for drug delivery devices for home care. This factor is also increasing the need for application-specific injection, inhalation, topical, and transdermal drug products that are designed to cater to the needs of caregivers and patients.
Challenges: Pricing pressure
Government bodies in both developed and developing countries are encouraging cost-saving measures, such as cutting drug reimbursement prices and promoting the greater use of generics. Drug manufacturers across the globe are facing significant cost reduction pressures from government bodies, insurers, and patients. This downward pricing pressure is resulting in a greater uptake of drugs in emerging markets, where the demand for low-cost therapeutics is high. However, this is affecting the profitability of several pharmaceutical companies. This trend is expected to continue in the coming years due to ongoing pressure from insurers, pharmacy benefit managers (PBMs), and public and private payers to reduce pharmaceutical prices due to concerns about covering more new medicines to treat common conditions such as high cholesterol and diabetes.
The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period
Based on the route of administration, the pharmaceutical drug delivery market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery segment is expected to grow at the highest CAGR during the forecast period from 2021 to 2026. This can be attributed to convenience and ease of use, the ease of dosage, painless and non-invasive administration, and enhanced patient compliance.
In 2020, the infectious disease segment accounted for the largest share of the market
On the basis of application, the pharmaceutical drug delivery market is segmented into cancer, infectious diseases, cardiovascular diseases, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. In 2020, the infectious diseases segment accounted for the largest share of the global market. The large share of this market segment can be attributed to the increasing prevalence of infectious diseases across the globe, increasing R&D expenditure for new drugs owing to the current COVID-19 pandemic scenario, and the rising number of FDA approvals for such drugs.
The home care settings segment is expected to grow at the highest CAGR during the forecast period
Based on the facility of use, the pharmaceutical drug delivery market is segmented into hospitals, ambulatory surgery centers (ASCs) or clinics, home care settings, diagnostic centers, and other facilities of use. The home care settings segment is projected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the increasing use of drug delivery devices, such as injectables, nebulizers, and inhalers, in home care settings. Topical drug delivery systems are also increasingly gaining prominence, not just as an alternative route of drug delivery but also as point-of-care devices in in-home care settings.
North America will dominate the pharmaceutical drug delivery market from 2021–2026
Geographically, the global market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest share of this market in 2020. The high share of the North American market is attributed to the rising prevalence of chronic diseases, such as cancer, respiratory allergies, and diabetes; increasing patient compliance with innovative drug delivery technologies; and the presence of a large number of prominent players in this region.
To know about the assumptions considered for the study, download the pdf brochure
The prominent players in Pharmaceutical Drug Delivery Market are Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).
Pharmaceutical Drug Delivery Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$1656.9 billion |
|
Estimated Value by 2026 |
$2206.5 billion |
|
Growth Rate |
Poised to grow at a CAGR of 5.9% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Route of Administration, Application, Facility of Use |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
The study categorizes the pharmaceutical drug delivery market based on following segments an d sub-segments
By Route of Administration
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ocular Drug Delivery
- Pulmonary Drug Delivery
- Implantable Drug Delivery
- Transmucosal Drug Delivery
- Nasal Drug Delivery
By Application
- Infectious Diseases
- Cancer
- Cardiovascular Diseases
- Diabetes
- Respiratory Diseases
- Central Nervous System Disorders
- Autoimmune Diseases
- Other Applications
By Facility of Use
- Hospitals
- Ambulatory Surgery Centers
- Home Care Settings
- Diagnostic Centers
- Other Facilities of Use
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia
- China
- Japan
- India
- Rest of Asia
- Latin America
- Middle East & Africa
Recent Developments
- In July 2021, Johnson & Johnson received FDA approval for DARZALEX (daratumumab), a subcutaneous formulation that reduces the treatment time for multiple myeloma indications.
- In December 2020, Pfizer, Inc. received FDA approval for BRAFTOVI (encorafenib) plus combination with cetuximab for the treatment of patients with brafv600e-mutant metastatic colorectal cancer (CRC) who have undergone prior therapy.
- In November 2020, GlaxoSmithKline plc partnered with IDEAYA to enter the field of Synthetic Lethality, an emerging field in oncology; programs MAT2A, Pol Theta, and Werner Helicase programs, which are part of it, are projected to reach clinical trials in the next three years.
Frequently Asked Questions (FAQs):
What is the size of Pharmaceutical Drug Delivery Market?
The global pharmaceutical drug delivery market crossed $1,656.9 billion in 2021, and is poised to grow at a CAGR of 5.9% in the next five years to reach $2,206.5 billion.
Why is Pharmaceutical Drug Delivery Market Growing?
The pharmaceutical drug delivery market is growing due to several factors, such as increasing prevalence of chronic and lifestyle diseases, technological advancements in drug delivery systems, increasing demand for personalized medicines, rising geriatric population, and growing preference for self-administration of drugs. Additionally, the growth of the market is also driven by the increasing demand for biologics and specialty drugs, increasing R&D investments by pharmaceutical companies, and the growing focus on novel drug delivery technologies.
Who all are the key players in pharmaceutical drug delivery market?
The prominent players in Pharmaceutical Drug Delivery Market are Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 45)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION AND SCOPE
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 PHARMACEUTICAL DRUG DELIVERY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 49)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primaries
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 PHARMACEUTICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
FIGURE 8 PHARMACEUTICAL SALES APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE GLOBAL MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR
2.3 DATA TRIANGULATION APPROACH
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: GLOBAL MARKET
3 EXECUTIVE SUMMARY (Page No. - 64)
FIGURE 13 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD BILLION)
FIGURE 14 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 GLOBAL MARKET, BY FACILITY OF USE, 2021 VS. 2026 (USD BILLION)
FIGURE 16 GEOGRAPHIC ANALYSIS: GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 69)
4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET, BY FACILITY OF USE AND COUNTRY
FIGURE 18 THE HOSPITALS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER HIGHEST REVENUE GROWTH DURING FORECAST PERIOD
4.4 GLOBAL MARKET, BY REGION (2019-2026)
FIGURE 20 NORTH AMERICA TO DOMINATE THE MARKET DURING FORECAST PERIOD
4.5 GLOBAL MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 74)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 3 PHARMACEUTICAL DRUG DELIVERY MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of chronic diseases
5.2.1.2 Growth in the biologics market
TABLE 4 INDICATIVE LIST OF BIOLOGICS APPROVED BY THE FDA (2020)
5.2.1.3 Technological advancements and new product launches
5.2.1.4 Increasing investments in pharmaceutical R&D
FIGURE 22 NUMBER OF PHARMACEUTICAL COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020)
FIGURE 23 GLOBAL PHARMA R&D SPENDING (2016–2020)
5.2.2 MARKET RESTRAINTS
5.2.2.1 Risk of needlestick injuries
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Self-administration and home care
5.2.3.2 Rising demand for biosimilars and biologics
5.2.4 MARKET CHALLENGES
5.2.4.1 Pricing pressure
5.3 COVID-19 IMPACT ON THE GLOBAL MARKET
5.4 INDUSTRY TRENDS
5.4.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY TECHNOLOGIES
5.4.2 ADVANCEMENTS IN TECHNOLOGIES AND DESIGNS
5.5 REGULATORY ANALYSIS
TABLE 5 REGULATORY SCENARIO BY COUNTRY
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS (2020): GLOBAL MARKET
5.6.1 THREAT FROM NEW ENTRANTS
5.6.2 THREAT FROM SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET
5.8 ECOSYSTEM MAPPING
FIGURE 25 ECOSYSTEM OF THE GLOBAL MARKET
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
5.10 PATENT ANALYSIS
5.10.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
FIGURE 26 PATENT PUBLICATION, FILING, AND GRANT TRENDS (JANUARY 2011–OCTOBER 2021)
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 27 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021)
FIGURE 28 TOP APPLICANT COUNTRIES/REGIONS FOR PHARMACEUTICAL DRUG DELIVERY PATENTS (JANUARY 2011–OCTOBER 2021)
TABLE 7 SOME PATENTS/ PATENT APPLICATIONS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET, 2020-2021
6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 96)
6.1 INTRODUCTION
TABLE 8 MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
6.2 ORAL DRUG DELIVERY
TABLE 9 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 10 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.1 SOLID ORAL DRUGS
TABLE 11 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 12 ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.1.1 Tablets
6.2.1.1.1 The development of mini-tablets is a key trend in this market segment
TABLE 13 TABLETS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.1.2 Capsules
6.2.1.2.1 The easy absorption of drugs and decreased irritation in the GI tract drive the use of capsules
TABLE 14 CAPSULES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.1.3 Powders
6.2.1.3.1 Powders are taken by patients who are unable to swallow oral dosage forms
TABLE 15 POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.1.4 Pills
6.2.1.4.1 The rising incidence of target ailments to propel the growth of the pills market
TABLE 16 PILLS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.2 LIQUID ORAL DRUGS
TABLE 17 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 18 ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.2.1 Syrups
6.2.2.1.1 Syrups can be easily administered to patients with swallowing difficulties
TABLE 19 ORAL SYRUPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.2.2 Solutions
6.2.2.2.1 Solutions are generally preferred by geriatric and pediatric patients
TABLE 20 ORAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.3 SEMI SOLID ORAL DRUGS
TABLE 21 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 22 ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.3.1 Gels
6.2.3.1.1 Gels are used for controlled drug release
TABLE 23 ORAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.3.2 Emulsions
6.2.3.2.1 Microemulsions offer protection against oxidation and enzymatic hydrolysis
TABLE 24 ORAL EMULSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.2.3.3 Elixirs
6.2.3.3.1 Elixirs are hydraulic in nature and contain sweet and flavored substances
TABLE 25 ORAL ELIXIRS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 INJECTABLE DRUG DELIVERY
TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1 CONVENTIONAL INJECTION DEVICES
TABLE 28 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1.1 By material
TABLE 29 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
6.3.1.1.1 Glass Syringes
6.3.1.1.1.1 Glass syringes are considered to be one of the most durable and safest materials to store biological drugs
TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1.1.2 Plastic Syringes
6.3.1.1.2.1 Plastic syringes are reasonably priced as compared to their glass counterparts
TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1.2 By product
TABLE 32 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
6.3.1.2.1 Fillable syringes
6.3.1.2.1.1 Ease of use and the variable dosing formulations of fillable syringes to drive the market growth
TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1.2.2 Prefilled syringes
6.3.1.2.2.1 Prefilled syringes offer improved dose accuracy and increased patient convenience and safety
TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.1.3 By usability
TABLE 35 INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL INJECTION DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
6.3.1.3.1 Reusable syringes
6.3.1.3.1.1 Reusable syringes are easy to dismantle and clean
TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.1.3.2 Disposable syringes
6.3.1.3.2.1 Disposable syringes are widely used in medical practices due to their low cost and convenience
TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.2 SELF-INJECTION DEVICES
TABLE 38 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 39 INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.2.1 Needle-free injectors
6.3.2.1.1 Needle-free injectors enable faster drug delivery and show better reproducibility as compared to invasive drug delivery systems
TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.2.2 Autoinjectors
6.3.2.2.1 Autoinjectors to provide improved patient satisfaction as compared to manual injections
TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.2.3 Pen injectors
6.3.2.3.1 Pen injectors are generally used when medications have to be administered more than once a week
TABLE 42 COMMERCIALLY AVAILABLE KEY PEN INJECTORS
TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.2.4 Wearable injectors
6.3.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth
TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3.3 OTHER INJECTOR DEVICES
TABLE 45 OTHER INJECTORS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4 TOPICAL DRUG DELIVERY
TABLE 46 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 47 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.1 LIQUID FORMULATIONS
TABLE 48 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.1.1 Solutions
6.4.1.1.1 Ease of use and ready availability of the dosage form to support market growth
TABLE 50 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.1.2 Suspensions
6.4.1.2.1 Factors such as the high rate of bioavailability and the controlled onset of action to support the growth of the topical suspensions market
TABLE 51 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2 SEMI SOLID FORMULATIONS
TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 53 TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2.1 Creams
6.4.2.1.1 Creams are either water-in-oil or oil-in-water emulsions
TABLE 54 TOPICAL CREAMS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2.2 Gels
6.4.2.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels
TABLE 55 TOPICAL GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2.3 Ointments
6.4.2.3.1 Ointments are widely used in analgesic indications
TABLE 56 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2.4 Pastes
6.4.2.4.1 Topical pastes are widely used for the treatment and prevention of skin irritation
TABLE 57 TOPICAL PASTES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.2.5 Lotions
6.4.2.5.1 Easy administration of lotions to drive the demand among end users
TABLE 58 TOPICAL LOTIONS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.3 SOLID FORMULATIONS
TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.3.1 Suppositories
6.4.3.1.1 Suppositories require a suitable base to ensure the compatibility and stability of the drug
TABLE 61 TOPICAL SUPPOSITORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.3.2 Powders
6.4.3.2.1 Powders have a very fine particle size that covers a large surface area per unit weight
TABLE 62 TOPICAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.4 TRANSDERMAL PRODUCTS
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 64 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2019–2026 (USD BILLION)
6.4.4.1 Transdermal patches
6.4.4.1.1 Transdermal patches to prevent the premature metabolization of the drug through the liver
TABLE 65 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4.4.2 Transdermal gels
6.4.4.2.1 Transdermal gels to help in a faster release of drugs on the target site
TABLE 66 TRANSDERMAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5 OCULAR DRUG DELIVERY
TABLE 67 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 68 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.1 LIQUID FORMULATIONS
TABLE 69 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 70 OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.1.1 Eye drops
6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive the market growth
TABLE 71 COMMERCIALLY AVAILABLE EYE DROPS
TABLE 72 EYE DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.1.2 Liquid sprays
6.5.1.2.1 Liquid sprays to help in overcoming drawbacks associated with traditional eye drops
TABLE 73 LIQUID SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.2 SEMI SOLID FORMULATIONS
TABLE 74 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 75 OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.2.1 Gels
6.5.2.1.1 The high viscosity of drugs, prolonged drug release, and the ease of drug administration are factors contributing to market growth
TABLE 76 OCULAR GELS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.2.2 Eye ointments
6.5.2.2.1 Eye ointments are safe to use and help in improving ocular contact time with the drug
TABLE 77 EYE OINTMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5.3 OCULAR DEVICES
TABLE 78 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 79 OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY COUNTRY, 2019–2026 (USD BILLION)
6.5.3.1 Drug-coated contact lenses
6.5.3.1.1 Better eyesight offered by lenses and high compliance to drive the market for drug-coated contact lenses
TABLE 80 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.5.3.2 Ocular inserts
6.5.3.2.1 Ocular inserts to help in the sustained release of drugs in the eye
TABLE 81 OCULAR INSERTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.6 PULMONARY DRUG DELIVERY
TABLE 82 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 83 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.6.1 METERED-DOSE INHALERS
6.6.1.1 Metered-dose inhalers overcome the problem of poor coordination between inhaler actuation and patient breath
TABLE 84 PULMONARY DRUG DELIVERY MARKET FOR METERED-DOSE INHALERS, BY COUNTRY, 2019–2026 (USD BILLION)
6.6.2 DRY POWDER INHALERS
6.6.2.1 Dry powder inhaler formulations are chemically more stable than their counterparts
TABLE 85 PULMONARY DRUG DELIVERY MARKET FOR DRY POWDER INHALERS, BY COUNTRY, 2019–2026 (USD BILLION)
6.6.3 NEBULIZERS
TABLE 86 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 87 PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY COUNTRY, 2019–2026 (USD BILLION)
6.6.3.1 Jet nebulizers
6.6.3.1.1 Jet nebulizers account for the largest share of the nebulizers market
TABLE 88 JET NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.6.3.2 Ultrasonic nebulizers
6.6.3.2.1 Ultrasonic nebulizers are easy to use and comfortable to handle
TABLE 89 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.6.3.3 Soft mist nebulizers
6.6.3.3.1 Soft mist nebulizers are preferred for the treatment of severe COPD
TABLE 90 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.7 NASAL DRUG DELIVERY
TABLE 91 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 92 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.7.1 NASAL DROPS
6.7.1.1 Nasal drops are considered more efficient than nasal sprays
TABLE 93 NASAL DROPS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.7.2 NASAL SPRAYS
6.7.2.1 Nasal sprays to help in relieving nasal congestion, runny nose, itchy nose, and sneezing
TABLE 94 NASAL SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.7.3 NASAL POWDERS
6.7.3.1 The absence of preservatives and superior stability of formulations are some of the advantages associated with nasal powders
TABLE 95 NASAL POWDERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.7.4 NASAL GELS
6.7.4.1 Nasal gels provide long-lasting relief from dry nasal passages and also reduce irritation caused by using soothing excipients
TABLE 96 NASAL GELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.8 TRANSMUCOSAL DRUG DELIVERY
TABLE 97 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 98 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.8.1 ORAL FORMULATIONS
TABLE 99 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 100 TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
6.8.1.1 Buccal drug delivery
6.8.1.1.1 Buccal drug delivery system is suitable for local and systematic therapies
TABLE 101 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.8.1.2 Sublingual drug delivery
6.8.1.2.1 The rate of drug absorption through the sublingual route is 3–10 times higher than the oral route
TABLE 102 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
TABLE 103 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 104 TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
6.8.2.1 Rectal transmucosal drug delivery
6.8.2.1.1 The rectal route of drug delivery rapidly absorbs drugs that are aqueous in nature
TABLE 105 RECTAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.8.2.2 Vaginal transmucosal drug delivery
6.8.2.2.1 The permeability of the drug is high through the vaginal route of administration
TABLE 106 VAGINAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.9 IMPLANTABLE DRUG DELIVERY
TABLE 107 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 108 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.9.1 ACTIVE IMPLANTABLE DRUG DELIVERY
6.9.1.1 Active implantable devices are used for diagnostic monitoring, body fluids transportation, and ionizing radiation
TABLE 109 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.9.2 PASSIVE IMPLANTABLE DRUG DELIVERY
6.9.2.1 Passive implants primarily include joint replacements, heart valves, aneurysm clips, coronary stents, and breast implants
TABLE 110 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION (Page No. - 191)
7.1 INTRODUCTION
7.2 COVID-19 IMPACT, BY APPLICATION
TABLE 111 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
7.3 INFECTIOUS DISEASES
7.3.1 HIGH BURDEN OF INFECTIOUS DISEASES ACROSS THE GLOBE TO DRIVE MARKET GROWTH
TABLE 112 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
7.4 CANCER
7.4.1 CANCER TO FORM A KEY THERAPEUTIC APPLICATION SEGMENT FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
FIGURE 29 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020)
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS)
TABLE 113 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 114 GLOBAL MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION)
7.5 CARDIOVASCULAR DISEASES
7.5.1 INCREASING PREVALENCE OF CVDS AND INCREASING INNOVATION IN THE PHARMACEUTICAL DRUG DELIVERY SEGMENT TO PROPEL MARKET GROWTH
TABLE 115 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 116 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
7.6 DIABETES
7.6.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
TABLE 117 GLOBAL MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD BILLION)
7.7 RESPIRATORY DISEASES
7.7.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE THE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY
TABLE 118 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020)
TABLE 119 GLOBAL MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
7.8 CENTRAL NERVOUS SYSTEM DISORDERS
7.8.1 ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS ARE WIDELY USED IN THE TREATMENT OF CNS DISORDERS
TABLE 120 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
7.9 AUTOIMMUNE DISEASES
7.9.1 AUTOIMMUNE DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
TABLE 121 GLOBAL MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
7.10 OTHER APPLICATIONS
7.10.1 OPHTHALMIC DISORDERS
7.10.2 ENDOCRINE DISORDERS
TABLE 122 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. - 210)
8.1 INTRODUCTION
TABLE 123 MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
8.2 HOSPITALS
8.2.1 HOSPITALS DOMINATE THE GLOBAL MARKET WITH THE HIGH VOLUME OF PRESCRIPTIONS FOR INPATIENT AND OUTPATIENT VISITS
TABLE 124 MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD BILLION)
8.3 AMBULATORY SURGERY CENTERS/CLINICS
8.3.1 INCREASING PREFERENCE FOR AMBULATORY SURGERY CENTERS TO RESULT IN A SIGNIFICANT RISE IN DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
TABLE 125 GLOBAL MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD BILLION)
8.4 HOME CARE SETTINGS
8.4.1 HOME CARE SETTINGS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
TABLE 126 GLOBAL MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD BILLION)
8.5 DIAGNOSTIC CENTERS
8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
TABLE 127 GLOBAL MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD BILLION)
8.6 OTHER FACILITIES OF USE
TABLE 128 GLOBAL MARKET FOR OTHER FACILITIES OF USE, BY COUNTRY, 2019–2026 (USD BILLION)
9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION (Page No. - 219)
9.1 INTRODUCTION
FIGURE 32 GLOBAL MARKET: GEOGRAPHIC SNAPSHOT (2020)
TABLE 129 MARKET, BY REGION, 2019–2026 (USD BILLION)
9.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 130 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 131 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 132 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 133 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 134 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 135 NORTH AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION)
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 141 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 142 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 143 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 144 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 145 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 146 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 147 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 148 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 149 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 150 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 151 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 152 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 153 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 154 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 156 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 157 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 158 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.2.1 US
9.2.1.1 The US to dominate the North American market
TABLE 159 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 160 US: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 161 US: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 162 US: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 163 US: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION)
TABLE 165 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 166 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 167 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 168 US: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 169 US: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 170 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 171 US: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 172 US: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 173 US: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 174 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 175 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 176 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 177 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 178 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 179 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 180 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 182 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 183 US: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 184 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 185 US: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 186 US: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 187 US: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.2.2 CANADA
9.2.2.1 Government support for research and the prevalence of chronic diseases to drive the market in Canada
TABLE 188 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 189 CANADA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 190 CANADA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 191 CANADA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 192 CANADA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 193 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 194 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 195 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 196 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 197 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 198 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 199 CANADA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 200 CANADA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 201 CANADA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 202 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 203 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 204 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 205 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 206 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 207 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 208 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 210 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 211 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 213 CANADA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 214 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 215 CANADA: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3 EUROPE
TABLE 216 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 217 EUROPE: GLOBAL MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 218 EUROPE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 219 EUROPE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 220 EUROPE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 221 EUROPE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 222 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 223 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 224 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 225 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 226 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 227 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 228 EUROPE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 229 EUROPE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 230 EUROPE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 231 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 232 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 233 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 234 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 235 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 236 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 237 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 238 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 239 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 240 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 241 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 242 EUROPE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 243 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 244 EUROPE: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.1 GERMANY
9.3.1.1 Growing focus of pharmaceutical companies on the development of various drug delivery products to drive the market in Germany
TABLE 245 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 246 GERMANY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 247 GERMANY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 248 GERMANY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 249 GERMANY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 250 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 251 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 252 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 253 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 254 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 255 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 256 GERMANY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 257 GERMANY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 258 GERMANY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 259 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 260 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 261 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 262 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 263 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 264 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 265 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 266 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 267 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 268 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 269 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 270 GERMANY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 271 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 272 GERMANY: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.2 FRANCE
9.3.2.1 Presence of leading pharmaceutical companies along with the increasing prevalence of chronic diseases to drive market growth in France
TABLE 273 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 274 FRANCE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 275 FRANCE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 276 FRANCE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 277 FRANCE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 278 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 279 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 280 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 281 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 282 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD MILLION)
TABLE 283 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 284 FRANCE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 285 FRANCE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 286 FRANCE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 287 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 288 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 289 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 290 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 291 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 292 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 293 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 294 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 295 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 296 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 297 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 298 FRANCE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 299 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 300 FRANCE: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.3 ITALY
9.3.3.1 Increasing focus on clinical research and the growing popularity of branded drugs to drive the demand for pharmaceutical drug manufacturing
TABLE 301 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 302 ITALY: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 303 ITALY: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 304 ITALY: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 305 ITALY: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 306 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 307 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 308 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 309 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 310 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 311 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 312 ITALY: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 313 ITALY: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 314 ITALY: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 315 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 316 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 317 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 318 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 319 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 320 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 321 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 322 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 323 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 324 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 325 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 326 ITALY: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 327 ITALY: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 328 ITALY: MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.4 UK
9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive the demand for pharmaceutical drug delivery in the UK
TABLE 329 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 330 UK: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 331 UK: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 332 UK: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 333 UK: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 334 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 335 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 336 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 337 UK: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 338 UK: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 339 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 340 UK: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 341 UK: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 342 UK: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 343 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 344 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 345 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 346 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 347 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 348 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 349 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 350 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 351 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 352 UK: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 353 UK: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 354 UK: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 355 UK: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 356 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.5 SPAIN
9.3.5.1 Increase in biologics production to support market growth
TABLE 357 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 358 SPAIN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 359 SPAIN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 360 SPAIN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 361 SPAIN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 362 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 363 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 364 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 365 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 366 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 367 SPAIN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 368 SPAIN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 369 SPAIN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 370 SPAIN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 371 SPAIN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 372 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 373 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 374 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 375 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 376 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 377 SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MLLION)
TABLE 378 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 379 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 380 SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 381 SPAIN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 382 SPAIN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 383 SPAIN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 384 SPAIN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.3.6 REST OF EUROPE
TABLE 385 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 386 ROE: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 387 ROE: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 388 ROE: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 389 ROE: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 390 ROE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 391 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 392 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 393 ROE: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 394 ROE: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 395 ROE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 396 ROE: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 397 ROE: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 398 ROE: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 399 ROE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 400 ROE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 401 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 402 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 403 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 404 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 405 ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 406 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 407 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 408 ROE: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 409 ROE: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 410 ROE: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 411 ROE: MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 412 ROE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.4 ASIA PACIFIC
FIGURE 34 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 413 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 414 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 415 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 416 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 417 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 418 ASIA PACIFIC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 419 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 420 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 421 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 422 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 423 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 424 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 425 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 426 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 427 ASIA PACIFIC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 428 ASIA PACIFIC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 429 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 430 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 431 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 432 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 433 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 434 ASIA PACIFIC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 435 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 436 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 437 ASIA PACIFIC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 438 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 439 ASIA PACIFIC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 440 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 441 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.4.1 CHINA
9.4.1.1 China had the largest diabetic population in the world in 2020
TABLE 442 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 443 CHINA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 444 CHINA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 445 CHINA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 446 CHINA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 447 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 448 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 449 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 450 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 451 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 452 CHINA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 453 CHINA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 454 CHINA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 455 CHINA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 456 CHINA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 457 CHINA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 458 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 459 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 460 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 461 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 462 CHINA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 463 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 464 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 465 CHINA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 466 CHINA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 467 CHINA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 468 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 469 CHINA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.4.2 JAPAN
9.4.2.1 Favorable government initiatives and increased geriatric population to drive market growth in Japan
TABLE 470 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 471 JAPAN: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 472 JAPAN: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 473 JAPAN: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 474 JAPAN: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 475 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 476 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 477 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 478 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 479 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 480 JAPAN: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 481 JAPAN: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 482 JAPAN: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 483 JAPAN: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 484 JAPAN: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 485 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 486 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 487 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 488 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 489 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 490 JAPAN: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 491 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 492 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 493 JAPAN: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 494 JAPAN: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 495 JAPAN: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 496 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 497 JAPAN: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.4.3 INDIA
9.4.3.1 Growing generic demand and rising government initiatives to drive market growth in India
TABLE 498 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 499 INDIA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 500 INDIA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 501 INDIA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 502 INDIA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 503 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 504 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 505 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 506 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 507 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 508 INDIA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 509 INDIA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 510 INDIA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 511 INDIA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 512 INDIA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 513 INDIA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 514 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 515 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 516 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 517 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 518 INDIA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 519 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 520 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 521 INDIA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 522 INDIA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 523 INDIA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 524 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 525 INDIA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 526 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 527 ROAPAC: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 528 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 529 ROAPAC: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 530 ROAPAC: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 531 ROAPAC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 532 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 533 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 534 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 535 ROAPAC: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 536 ROAPAC: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 537 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 538 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 539 ROAPAC: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 540 ROAPAC: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 541 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 542 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 543 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 544 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 545 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 546 ROAPAC: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 547 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 548 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 549 ROAPAC: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 550 ROAPAC: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 551 ROAPAC: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 552 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 553 ROAPAC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.5 LATIN AMERICA
9.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
TABLE 554 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 555 LATIN AMERICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 556 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 557 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 558 LATIN AMERICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 559 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 560 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 561 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 562 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 563 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 564 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 565 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 566 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 567 LATIN AMERICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 568 LATIN AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 569 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 570 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 571 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 572 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 573 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 574 LATIN AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 575 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 576 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 577 LATIN AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 578 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 579 LATIN AMERICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 580 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 581 LATIN AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 GOVERNMENT SUPPORT BOOSTING LOCAL PRODUCTION TO OFFER GROWTH OPPORTUNITIES FOR PHARMACEUTICAL MANUFACTURERS
TABLE 582 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019–2026 (USD BILLION)
TABLE 583 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 584 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 585 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR LIQUID DRUGS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 586 MIDDLE EAST & AFRICA: ORAL DRUG DELIVERY MARKET FOR SEMI SOLID DRUGS, BY DOSAGE FORM, 2019–2026 (USD MILLION)
TABLE 587 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 588 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY MATERIAL, 2019–2026 (USD BILLION)
TABLE 589 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 590 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR CONVENTIONAL DEVICES, BY USABILITY, 2019–2026 (USD BILLION)
TABLE 591 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR SELF-INJECTION DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 592 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 593 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 594 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 595 MIDDLE EAST & AFRICA: OCULAR DRUG DELIVERY MARKET FOR OCULAR DEVICES, BY TYPE, 2019–2026 (USD BILLION)
TABLE 596 MIDDLE EAST & AFRICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2019–2026 (USD MILLION)
TABLE 597 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 598 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 599 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 600 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY DOSAGE FORM, 2019–2026 (USD BILLION)
TABLE 601 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 602 MIDDLE EAST & AFRICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 603 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 604 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR ORAL FORMULATIONS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 605 MIDDLE EAST & AFRICA: TRANSMUCOSAL DRUG DELIVERY MARKET FOR OTHER FORMULATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 606 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 607 MIDDLE EAST & AFRICA: PULMONARY DRUG DELIVERY MARKET FOR NEBULIZERS, BY TYPE, 2019–2026 (USD BILLION)
TABLE 608 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 609 MIDDLE EAST & AFRICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2019–2026 (USD BILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 410)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE PHARMACEUTICAL DRUG DELIVERY MARKET
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
10.4 MARKET SHARE ANALYSIS
FIGURE 36 PHARMACEUTICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2020
TABLE 610 PHARMACEUTICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE BENCHMARKING
TABLE 611 FOOTPRINT OF COMPANIES IN THE PHARMACEUTICAL DRUG DELIVERY MARKET
TABLE 612 COMPANY PRODUCT OFFERING FOOTPRINT (20 COMPANIES)
TABLE 613 COMPANY APPLICATION FOOTPRINT (20 COMPANIES)
TABLE 614 COMPANY FACILITY OF USE FOOTPRINT (20 COMPANIES)
TABLE 615 COMPANY REGION FOOTPRINT (20 COMPANIES)
10.6 COMPETITIVE LEADERSHIP MAPPING
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 37 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
10.7 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
10.7.1 PROGRESSIVE COMPANIES
10.7.2 DYNAMIC COMPANIES
10.7.3 STARTING BLOCKS
10.7.4 RESPONSIVE COMPANIES
FIGURE 38 PHARMACEUTICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES & APPROVALS
10.8.2 DEALS
10.8.3 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 426)
11.1 KEY PLAYERS
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.1.1 JOHNSON & JOHNSON
TABLE 619 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
11.1.2 NOVARTIS INTERNATIONAL AG
TABLE 620 NOVARTIS INTERNATIONAL AG: BUSINESS OVERVIEW
FIGURE 40 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2020)
11.1.3 F. HOFFMANN-LA ROCHE AG
TABLE 621 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
11.1.4 PFIZER INC.
TABLE 622 PFIZER INC. : BUSINESS OVERVIEW
FIGURE 42 PFIZER INC.: COMPANY SNAPSHOT (2020)
11.1.5 BECTON, DICKINSON AND COMPANY
TABLE 623 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.6 GLAXOSMITHKLINE PLC
TABLE 624 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
FIGURE 44 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)
11.1.7 MERCK & CO., INC.
TABLE 625 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
11.1.8 SANOFI
TABLE 626 SANOFI: BUSINESS OVERVIEW
FIGURE 46 SANOFI: COMPANY SNAPSHOT (2020)
11.1.9 BAYER AG
TABLE 627 BAYER AG: BUSINESS OVERVIEW
FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2020)
11.1.10 3M
TABLE 628 3M: BUSINESS OVERVIEW
FIGURE 48 3M: COMPANY SNAPSHOT (2020)
11.1.11 ANTARES PHARMA, INC.
TABLE 629 ANTARES PHARMA, INC.: BUSINESS OVERVIEW
11.1.12 AMGEN, INC.
TABLE 630 AMGEN, INC. : BUSINESS OVERVIEW
FIGURE 49 AMGEN, INC. : COMPANY SNAPSHOT (2020)
11.1.13 ABBVIE INC.
TABLE 631 ABBVIE INC.: BUSINESS OVERVIEW
11.1.14 GENMAB A/S
TABLE 632 GENMAB A/S : BUSINESS OVERVIEW
11.1.15 GILEAD SCIENCES, INC.
TABLE 633 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW
11.1.16 BOEHRINGER INGELHEIM
TABLE 634 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
FIGURE 50 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
11.1.17 ASTRAZENECA PLC
TABLE 635 ASTRAZENECA PLC: BUSINESS OVERVIEW
FIGURE 51 ASTRAZENECA: COMPANY SNAPSHOT (2020)
11.1.18 ELI LILLY AND COMPANY
TABLE 636 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 637 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
11.1.20 BRISTOL-MYERS SQUIBB
TABLE 638 BRISTOL-MYERS SQUIBB: BUSINESS OVERVIEW
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 GERRESHEIMER AG
11.2.2 BOSTON SCIENTIFIC CORPORATION
11.2.3 NIMBUS THERAPEUTICS
11.2.4 KITE PHARMA
11.2.5 IDEAYA BIOSCIENCES, INC.
12 APPENDIX (Page No. - 545)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the use of widespread secondary sources; directories; databases, such as D&B, Bloomberg Business, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the pharmaceutical drug delivery market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the pharmaceutical drug delivery market. Primary participants mainly include CEOs, consultants, subject-matter experts, SIU directors, claims processing personnel, general managers, and sales executives.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Pharmaceutical Drug Delivery Market Size Estimation
The total size of the pharmaceutical drug delivery market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of the approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, and forecast the pharmaceutical drug delivery market by route of administration, facility of use, application, and region
- To provide detailed information regarding factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical drug delivery market
- To analyze the market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the pharmaceutical drug delivery market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the pharmaceutical drug delivery market and comprehensively analyze their core competencies2 and market shares
- To track and analyze competitive developments, such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and product approvals of the leading players in the pharmaceutical drug delivery market
- To benchmark players within the pharmaceutical drug delivery market using the competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Latin America pharmaceutical drug delivery market into Brazil, Mexico, and other countries
- Further breakdown of the MEA (the Middle East & Africa) pharmaceutical drug delivery market into the UAE, Saudi Arabia, and other MEA countries
Growth opportunities and latent adjacency in Pharmaceutical Drug Delivery Market
Looking forward to gain more insights on the global Pharmaceutical Drug Delivery Market
What are the growth opportunities in Pharmaceutical Drug Delivery Market?
Can you enlighten us on the end users in Pharmaceutical Drug Delivery Market?